Vanda Pharmaceuticals Reports Positive Results in Motion Sickness Trial

The FDA has not approved a new medication for motion sickness in over 40 years, and Vanda Pharmaceuticals (Nasdaq: VNDA) may be on track to change that. The company’s share price rose by 5.0% on Wednesday after it reported positive results from a second Phase 3 clinical trial evaluating tradipitant in motion sickness. Vanda said that the study’s results confirmed previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness.

Vanda’s study was a multicenter, randomized, double-blind, placebo-controlled study that enrolled 316 participants with a prior history of motion sickness who were observed on boat trips under varied sea conditions. The study involved 20 boat trips off the US coast between September 2023 and April 2024. The study’s primary endpoint was the effect of tradipitant 170 mg on vomiting. Vanda reported that two doses of tradipitant, 170 mg and 85 mg, were shown to be superior to placebo in preventing vomiting.

Vanda expects to submit a New Drug Application (NDA) for tradipitant in motion sickness to the FDA in the fourth quarter of 2024.

Approximately 30% of the general population is reported to suffer from motion sickness under ordinary travel conditions.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.